Rep. Emily Randall Sells Amgen Inc. (NASDAQ:AMGN) Stock

Representative Emily Randall (D-Washington) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Amgen Price Performance

Shares of AMGN traded up $1.91 during trading hours on Thursday, reaching $296.97. The company had a trading volume of 2,060,730 shares, compared to its average volume of 3,224,222. The firm has a 50 day simple moving average of $273.29 and a 200-day simple moving average of $302.18. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $159.63 billion, a price-to-earnings ratio of 39.33, a PEG ratio of 3.01 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Research analysts expect that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is currently 119.21%.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the stock. Belpointe Asset Management LLC raised its holdings in shares of Amgen by 20.2% during the fourth quarter. Belpointe Asset Management LLC now owns 9,760 shares of the medical research company’s stock worth $2,544,000 after purchasing an additional 1,638 shares during the period. CreativeOne Wealth LLC raised its holdings in shares of Amgen by 26.4% during the fourth quarter. CreativeOne Wealth LLC now owns 13,132 shares of the medical research company’s stock worth $3,423,000 after purchasing an additional 2,740 shares during the period. Mariner LLC raised its holdings in shares of Amgen by 2.2% during the fourth quarter. Mariner LLC now owns 914,380 shares of the medical research company’s stock worth $238,316,000 after purchasing an additional 19,250 shares during the period. Savvy Advisors Inc. raised its holdings in shares of Amgen by 5.1% during the fourth quarter. Savvy Advisors Inc. now owns 42,940 shares of the medical research company’s stock worth $11,192,000 after purchasing an additional 2,087 shares during the period. Finally, Synovus Financial Corp increased its holdings in shares of Amgen by 0.3% in the 4th quarter. Synovus Financial Corp now owns 65,729 shares of the medical research company’s stock worth $17,137,000 after acquiring an additional 165 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Bank of America lifted their price target on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $314.09.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.